Development and Evaluation of Solid Lipid Nanoparticles of Raloxifene Hydrochloride for Enhanced Bioavailability

Table 4

Pharmacokinetic data of RL-HCL suspension and RL-HCL loaded SLN.

Sample	𝑇max (hr)	𝐶max (ng/mL)	AUC0--24 (ng * hr/mL)	AUC0--∞  (ng * hr/mL)	MRT0--𝑡	𝑡1/2 (hr)
RL-HCL; suspension	8.0	40.67±6.67	409.6±34.51	436.66±14.57	13.51±1.8	9.63±2.9
RL-HCL; Loaded SLN	2.0	386.33±80.61	2063.26±94.4	2258.3±85.34	6.68±1.1	4.74±1.5

Mean ± SD; 𝑛=3.